RU2355691C2 - Полиморфные и аморфная формы фосфатной соли 8-фтор-2-{4-[(метиламино)метил]фенил}-1,3,4,5-тетрагидро-6н-азепино[5.4.3-cd]индол-6-она - Google Patents

Полиморфные и аморфная формы фосфатной соли 8-фтор-2-{4-[(метиламино)метил]фенил}-1,3,4,5-тетрагидро-6н-азепино[5.4.3-cd]индол-6-она Download PDF

Info

Publication number
RU2355691C2
RU2355691C2 RU2007110026/04A RU2007110026A RU2355691C2 RU 2355691 C2 RU2355691 C2 RU 2355691C2 RU 2007110026/04 A RU2007110026/04 A RU 2007110026/04A RU 2007110026 A RU2007110026 A RU 2007110026A RU 2355691 C2 RU2355691 C2 RU 2355691C2
Authority
RU
Russia
Prior art keywords
compound
methyl
fluoro
methylamino
tetrahydro
Prior art date
Application number
RU2007110026/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2007110026A (ru
Inventor
Джиа ЛИУ (US)
Джиа ЛИУ
Нареш НАЙЯР (US)
Нареш НАЙЯР
Минг ГУО (US)
Минг ГУО
Жен-Пинг ВУ (US)
Жен-Пинг ВУ
Беннетт Шаплин БОРЕР (US)
Беннетт Шаплин БОРЕР
Апарна Надиг ШРИРАНГАМ (US)
Апарна Надиг ШРИРАНГАМ
Марк Брайан МИТЧЕЛЛ (US)
Марк Брайан МИТЧЕЛЛ
Йи ЛИ (US)
Йи Ли
Джан-Джон ЧУ (US)
Джан-Джон ЧУ
Original Assignee
Пфайзер Инк.
Кансер Рисерч Текнолоджи Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк., Кансер Рисерч Текнолоджи Лтд. filed Critical Пфайзер Инк.
Publication of RU2007110026A publication Critical patent/RU2007110026A/ru
Application granted granted Critical
Publication of RU2355691C2 publication Critical patent/RU2355691C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2007110026/04A 2004-09-22 2005-09-12 Полиморфные и аморфная формы фосфатной соли 8-фтор-2-{4-[(метиламино)метил]фенил}-1,3,4,5-тетрагидро-6н-азепино[5.4.3-cd]индол-6-она RU2355691C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61245904P 2004-09-22 2004-09-22
US60/612,459 2004-09-22
US67929605P 2005-05-09 2005-05-09
US60/679,296 2005-05-09

Publications (2)

Publication Number Publication Date
RU2007110026A RU2007110026A (ru) 2008-10-27
RU2355691C2 true RU2355691C2 (ru) 2009-05-20

Family

ID=35526956

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007110026/04A RU2355691C2 (ru) 2004-09-22 2005-09-12 Полиморфные и аморфная формы фосфатной соли 8-фтор-2-{4-[(метиламино)метил]фенил}-1,3,4,5-тетрагидро-6н-азепино[5.4.3-cd]индол-6-она

Country Status (17)

Country Link
US (1) US7268126B2 (enExample)
EP (1) EP1799685B1 (enExample)
JP (1) JP2008513436A (enExample)
KR (1) KR100853601B1 (enExample)
AR (1) AR051296A1 (enExample)
AT (1) ATE551345T1 (enExample)
AU (1) AU2005286191B2 (enExample)
BR (1) BRPI0516766A (enExample)
CA (1) CA2581025C (enExample)
ES (1) ES2382950T3 (enExample)
IL (1) IL181463A (enExample)
MX (1) MX2007002461A (enExample)
NO (1) NO337938B1 (enExample)
NZ (1) NZ554659A (enExample)
RU (1) RU2355691C2 (enExample)
TW (1) TWI365188B (enExample)
WO (1) WO2006033007A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2570198C2 (ru) * 2010-02-12 2015-12-10 Пфайзер Инк. СОЛИ И ПОЛИМОРФЫ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5-ТЕТРАГИДРО-6Н-АЗЕПИНО[5,4,3-cd]ИНДОЛ-6-ОНА

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1611137A1 (en) * 2003-03-31 2006-01-04 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
SG164368A1 (en) * 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
AU2007292306A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
AU2007292387A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
WO2008114114A2 (en) * 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
NZ586123A (en) * 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors
KR20100102609A (ko) * 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법
CA2708157A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
KR20100112192A (ko) * 2008-02-04 2010-10-18 바이파 사이언스 인코포레이티드 Ｐａｒｐ－매개된 질병을 진단 및 치료하는 방법
KR20170095402A (ko) 2009-11-09 2017-08-22 알러간, 인코포레이티드 모발 성장을 촉진하기 위한 조성물 및 방법
WO2011141909A2 (en) 2010-05-10 2011-11-17 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
AU2014216112B2 (en) 2013-02-15 2019-02-21 Allergan, Inc. Sustained drug delivery implant
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
RS67356B1 (sr) 2014-08-22 2025-11-28 Pharma& Schweiz Gmbh Tablete rukapariba visoke doze
JP6457696B2 (ja) 2015-07-23 2019-01-23 アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
US10875870B2 (en) 2017-01-24 2020-12-29 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CN110997068B (zh) 2017-05-24 2022-12-06 宾夕法尼亚大学董事会 用于成像和放射疗法的经放射标记的荧光parp抑制剂
MX2020004545A (es) * 2017-11-03 2020-08-03 Sandoz Ag Sal cristralina de un inhibidor triciclico de poli(adp-ribosa)-polimerasa.
US10933069B2 (en) 2018-01-05 2021-03-02 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
US10442813B2 (en) 2018-01-30 2019-10-15 RK Pharma Solutions LLC Polymorphs of rucaparib camsylate and methods of making same
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
PH12022550037A1 (en) 2019-07-10 2023-04-12 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics
EP3997093A1 (en) 2019-07-10 2022-05-18 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4100125A1 (en) 2020-02-03 2022-12-14 Sandoz AG Polymorph of rucaparib mesylate
ES3014370T3 (en) 2020-04-28 2025-04-22 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
EP4182318B1 (en) 2020-07-14 2025-08-27 Assia Chemical Industries Ltd. Solid state forms of rucaparib salts
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
AU2022255809A1 (en) 2021-04-08 2023-10-26 Incozen Therapeutics Pvt. Ltd. Inhibitors of poly(adp-ribose) polymerase
EP4463232A1 (en) 2022-01-11 2024-11-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US649554A (en) * 1899-04-08 1900-05-15 Ferdinand Schwedtmann Electric switch.
SU1748647A3 (ru) * 1988-03-18 1992-07-15 Жансен Фармасетика Н.В. (Фирма) Способ получени тетрагидроимидазо-(1,4)-бензодиазепин-12-онов, или их солей присоединени фармацевтически приемлемых кислот, или их стереохимически изомерных форм
RU93004873A (ru) * 1990-08-24 1995-08-20 Фудзисава Фармасьютикал Ко., Лтд. Трициклические бензодиазепиновые производные, способ их получения, фармацевтическая композиция и способ лечения

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL210415B1 (pl) * 1999-01-11 2012-01-31 Agouron Pharma Pochodne indolu, środek farmaceutyczny i zastosowanie pochodnych indolu
EP1611137A1 (en) * 2003-03-31 2006-01-04 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
ATE454893T1 (de) * 2003-07-25 2010-01-15 Cancer Rec Tech Ltd Tricyclische parp-hemmer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US649554A (en) * 1899-04-08 1900-05-15 Ferdinand Schwedtmann Electric switch.
SU1748647A3 (ru) * 1988-03-18 1992-07-15 Жансен Фармасетика Н.В. (Фирма) Способ получени тетрагидроимидазо-(1,4)-бензодиазепин-12-онов, или их солей присоединени фармацевтически приемлемых кислот, или их стереохимически изомерных форм
RU93004873A (ru) * 1990-08-24 1995-08-20 Фудзисава Фармасьютикал Ко., Лтд. Трициклические бензодиазепиновые производные, способ их получения, фармацевтическая композиция и способ лечения

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2570198C2 (ru) * 2010-02-12 2015-12-10 Пфайзер Инк. СОЛИ И ПОЛИМОРФЫ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5-ТЕТРАГИДРО-6Н-АЗЕПИНО[5,4,3-cd]ИНДОЛ-6-ОНА

Also Published As

Publication number Publication date
NZ554659A (en) 2010-08-27
ES2382950T3 (es) 2012-06-14
EP1799685A2 (en) 2007-06-27
EP1799685B1 (en) 2012-03-28
WO2006033007A3 (en) 2006-11-02
KR100853601B1 (ko) 2008-08-22
AR051296A1 (es) 2007-01-03
US20060100198A1 (en) 2006-05-11
CA2581025C (en) 2011-06-07
TWI365188B (en) 2012-06-01
AU2005286191A1 (en) 2006-03-30
MX2007002461A (es) 2008-03-13
TW200613305A (en) 2006-05-01
ATE551345T1 (de) 2012-04-15
RU2007110026A (ru) 2008-10-27
CA2581025A1 (en) 2006-03-30
US7268126B2 (en) 2007-09-11
HK1116483A1 (en) 2008-12-24
AU2005286191B2 (en) 2011-11-17
JP2008513436A (ja) 2008-05-01
IL181463A (en) 2012-02-29
IL181463A0 (en) 2007-07-04
BRPI0516766A (pt) 2008-09-16
WO2006033007A2 (en) 2006-03-30
NO20070920L (no) 2007-03-15
NO337938B1 (no) 2016-07-11
KR20070089121A (ko) 2007-08-30

Similar Documents

Publication Publication Date Title
RU2355691C2 (ru) Полиморфные и аморфная формы фосфатной соли 8-фтор-2-{4-[(метиламино)метил]фенил}-1,3,4,5-тетрагидро-6н-азепино[5.4.3-cd]индол-6-она
JP6371350B2 (ja) ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６Ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンの塩および多形体
CN101133061B (zh) 8-氟-2-{4-[（甲基氨基）甲基]苯基}-1,3,4,5-四氢-6H-氮杂卓并[5,4,3-cd]吲哚-6-酮的磷酸盐的多晶型物和非晶物
HK1116483B (en) Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one